Treatment of advanced malignant melanoma with high‐dose chemotherapy and autologous bone marrow transplantation Preliminary results—Phase I study
Treatment of advanced malignant melanoma with high‐dose chemotherapy and autologous bone marrow transplantation Preliminary results—Phase I study
复制标题
大剂量化疗联合自体骨髓移植治疗晚期恶性黑色素瘤初步结果—I期研究
DOI：
--
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
J. Sutherland
中科院分区：
文献类型：
--
作者：
M. R. Thomas;W. Robinson;L. Glodé;M. Dantas;H. Koeppler;N. Morton;J. Sutherland
13例晚期（III期）恶性黑色素瘤患者接受了大剂量化疗（氮芥或BCNU和美法仑联合）联合自体非冷冻骨髓移植治疗。3例患者（24%）在26、60和73周时达到完全缓解，目前存活且无疾病，无需进一步治疗。5例患者（38%）达到部分缓解，5例患者（38%）无应答。对氮芥和卡努-美法仑组合的反应率没有差异。然而，氮芥的严重副作用排除了其在本研究中的进一步使用。患者死亡的主要原因是脑内转移，在未来的研究中提出了预防性脑照射的问题。对外周血中性粒细胞、血小板、外周血和骨髓CFU-C恢复率的研究表明，自体骨髓输注可能有利于缩短强化化疗后的造血恢复。
THIRTEEN PATIENTS WITH ADVANCED (STAGE III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation. Three patients (24%) achieved a complete remission and are currently alive and free of disease without further therapy at 26, 60, and 73 weeks. Five patients (38%) achieved partial remissions and five patients (38%) had no response. There was no difference in the response rate to nitrogen mustard and the BCNU-melphalan combination. Severe side effects to nitrogen mustard, however, precluded its further use in this study. The major cause of death in patients was intracerebral metastases, raising the question of prophylactic brain irradiation in future studies. Studies of the recovery rate of peripheral blood neutrophil, platelet, and peripheral blood and bone marrow CFU-C suggest that autologous bone marrow infusion may be of benefit in shortening hematopoietic recovery following intensive chemotherapy.